Searching for factors associated with resistance to acetylsalicylic acid used for secondary prevention of stroke
نویسندگان
چکیده
INTRODUCTION The aim of the study was to evaluate the prevalence of resistance to acetylsalicylic acid (ASA), used for secondary prevention of stroke, including the assessment of risk factors associated with the lack of ASA anti-aggregatory action. MATERIAL AND METHODS Patients after a transient ischaemic attack (TIA) or ischaemic stroke in the acute (n = 111) and chronic phase (n = 87) were enrolled in the study. The assessment of platelet function was performed by whole blood impedance aggregometry using a multi-channel platelet function analyser (Multiplate). RESULTS A proper response to ASA was found in 121 patients (61.1%) (ASA responders), a partial response to ASA in 59 patients (29.8%) (ASA partial responders), and ASA resistance in 18 patients (9.1%) (ASA non-responders). Acetylsalicylic acid resistance was observed more frequently in the chronic phase. The mean low-density lipoprotein (LDL) concentration was higher in ASA non-responders (p = 0.02). The mean heart rate (p = 0.03) and the mean haematocrit (p = 0.03) were higher in the group of ASA partial responders and ASA non-responders. Angiotensin II receptor antagonists were more often used in the group of ASA partial responders and ASA non-responders (p = 0.04). Diuretics were more rarely used by ASA non-responders, whereas fibrates were more rarely used by ASA partial responders. CONCLUSIONS The method enabled the detection of ASA resistance in some patients with cerebrovascular disease. The study revealed some possible risk factors of ASA resistance: long ASA therapy, increased heart rate, higher LDL concentration, and higher haematocrit value. The relationship between the effect of ASA and other medications (angiotensin II receptor blockers, fibrates, diuretics) requires further study. Platelet function monitoring should be considered in patients at a greater risk of ASA resistance.
منابع مشابه
Drug resistance and secondary treatment of ischaemic stroke: The genetic component of the response to acetylsalicylic acid and clopidogrel.
INTRODUCTION Cerebrovascular diseases are among the leading causes of death and disability in developed countries. Acetylsalicylic acid (ASA) and clopidogrel are the most widely-used antiplatelet drugs for secondary prevention of recurrent thromboembolic events. However, there have been cases in which antiplatelet drugs did not inhibit platelet activity; this phenomenon is called resistance, an...
متن کاملAn Overview of Prophylactic Acetylsalicylic Acid for the Prevention of Intra-uterine Growth Restriction (IUGR) in Women at Risk for Preeclampsia
Background: Preeclampsia is a major global cause of maternal, neonatal and perinatal mortality. The aim of this review was to summarize all reviews on Acetylsalicylic Acid for the prevention of Intra-uterine Growth Restriction (IUGR) in women at risk for Preeclampsia. Materials and Methods: In this overview we searched databases followin...
متن کاملComparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study
BACKGROUND In patients with ischemic stroke of non-cardioembolic origin, acetylsalicylic acid, clopidogrel, or a combination of acetylsalicylic acid and dipyridamole are recommended for the prevention of a recurrent stroke. The purpose of this study was to examine the risk of bleeding or recurrent stroke associated with these three treatments. METHODS Patients who were discharged with first-t...
متن کاملLow-dose acetylsalicylic acid for primary prevention of cardiovascular disease: Do not misinterpret the recommendations.
L ow-dose acetylsalicylic acid (ASA) for prevention of cardiovascular disease (CVD), including myocardial infarction (MI) and stroke, is likely something that comes up frequently at family physician appointments. Acetylsalicylic acid has substantial benefits for secondary prevention in most cases. Based on current recommendations, most would also agree that the benefits of ASA (risk reduction o...
متن کاملEuropean stroke prevention study: effectiveness of antiplatelet therapy in diabetic patients in secondary prevention of stroke.
BACKGROUND AND PURPOSE The European Stroke Prevention Study was a multicenter trial comparing the effect of a combination of 75 mg dipyridamole and 330 mg acetylsalicylic acid three times a day with the effect of a placebo in the prevention of stroke or death in 1,861 patients after one or more episodes of recent transient ischemic attack or cerebral infarction. METHODS The present study repr...
متن کامل